Clinical trials: Chronic Obstructive Pulmonary
Pulmonary Disease, Chronic Obstructive
Drug Use Survey of RESPIMAT in Patients With COPD
To investigate safety and effectiveness information on the use of Tiotropium Respimat for long time of period in daily practical clinical circumstances, and to obtain proper drug use information.
- Trial name
- NCT01145053
- Volunteers
- 361 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to assess the maintenance bronchodilator effects of the fixed dose combination versus monotherapies.
- Trial name
- NCT01437397
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate
- Where
- 222 sites in United States, Australia and 2 more
- Volunteers
- 1,692 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01054885
- Testing
- FF Inhalation Powder, FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
- Where
- 149 sites in United States, Argentina and 7 more
- Volunteers
- 1,226 people
- Sponsor
- GlaxoSmithKline
Coronary Artery Disease, Asthma
Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)
The goal of this research is to determine the utility of Regadenoson (Lexiscan)for use as an imaging agent with cardiac MR. If found useful, it will help us establish a protocol for regadenoson stress MR perfusion (Regadenoson…
- Conditions
- Coronary Artery Disease, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Angina
- Trial name
- NCT00763035
- Testing
- Regadenoson, Dobutamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
Pulmonary Disease, Chronic Obstructive
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
The primary objective of the present study is to evaluate the effect of tiotropium + olodaterol fixed dose combination (FDC) compared to tiotropium monotherapy on the intensity of breathlessness during the 3min constant speed…
- Trial name
- NCT02853123
- Testing
- Tiotropium, Olodaterol
- Where
- 13 sites in Belgium, Canada and 2 more
- Volunteers
- 106 people
- Sponsor
- Boehringer Ingelheim
COPD, Heart Failure
Personalized Experiences to Inform Improved Communication for Minorities With Life Limiting Illness
The purpose of this research is to develop patient-centered palliative care interventions to improve patient-provider communication and Quality of Life (QoL) of ethnic and racial minority patients living with life-limiting…
- Conditions
- COPD, Heart Failure, Cancer
- Trial name
- NCT03391115
- Testing
- Storytelling Intervention for Patient Participants, Storytelling Intervention for Nurse Participants
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Chronic Obstructive Pulmonary Disease
Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol
This study investigated the effect of exercise and high-dose salbutamol on the maximum heart rate in patients with chronic obstructive pulmonary disease (COPD) receiving therapeutic doses of indacaterol, salmeterol and placebo.
- Trial name
- NCT00531050
- Testing
- Indacaterol, Salmeterol
- Where
- Belgium
- Volunteers
- 27 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose
This is a Phase I open-label, single center study to assess the PK and safety of BGF MDI 320/14.4/9.6 µg in subjects with moderate to severe COPD.
- Trial name
- NCT03250182
- Testing
- PT010
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Lung Disease
Effect of Symbicort ® on GR in Sputum in COPD
The purpose of the research (or "knowledge gap" this research is designed to fill) is to understand the science of how the combination therapy of 2 drugs (inhaled longacting beta-agonists(LABA) and inhaled corticosteroids (ICS)…
- Trial name
- NCT01787097
- Testing
- Symbicort® total dose 400ug/12ug, Symbicort® total dose 800ug/24ug, Formoterol 24ug
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Imperial College London
Chronic Obstructive Pulmonary Disease
Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity
This study compared the effects of a single dose of indacaterol with that of a single dose of tiotropium on inspiratory capacity.
- Trial name
- NCT00999908
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 11 sites in Italy
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Low Back Pain, Patient Acceptance of Health Care
Veterans Response to Dosage in Chiropractic Therapy
This study evaluates how Veterans with chronic low back pain (cLBP) respond to varying doses of chiropractic therapy and how health services utilization are impacted as a result. There are 2 phases in this study.
- Conditions
- Low Back Pain, Patient Acceptance of Health Care, Veterans Health
- Trial name
- VERDICT (NCT04087291)
- Testing
- Chiropractic Care
- Where
- 4 sites in United States
- Volunteers
- 766 people
- Sponsor
- Palmer College of Chiropractic
Chronic Obstructive Pulmonary Disease
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
- Trial name
- SPARK (NCT01120691)
- Testing
- QVA149, NVA237, tiotropium
- Where
- 342 sites in United States, Argentina and 26 more
- Volunteers
- 2,224 people
- Sponsor
- Novartis Pharmaceuticals
COPD
Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort
This study will investigate whether switching symptomatic COPD patients from a fixed-dose combination of salmeterol/fluticasone 50/500 µg b.i.d. to a fixed dose combination of QVA149 110/50 µg o.d.
- Trial name
- FLASH (NCT02516592)
- Testing
- QVA149 110/50 micrograms, Salmeterol/fluticasone 50/500 microgrammes
- Where
- 64 sites in Australia, Egypt and 9 more
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler®…
- Trial name
- NCT01694771
- Testing
- Tiotropium, Olodaterol
- Where
- 90 sites in United States
- Volunteers
- 1,134 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with…
- Trial name
- NCT01323634
- Testing
- Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
- Where
- 50 sites in United States, Czechia and 4 more
- Volunteers
- 519 people
- Sponsor
- GlaxoSmithKline
COPD
COPD Access to Pulmonary Rehabilitation Intervention
Persons with COPD have significant functional disability but cannot access rehabilitative treatment at hospital-based conventional pulmonary rehabilitation (PR) programs.
- Trial name
- CAPRI (NCT03794921)
- Testing
- Every Step Counts
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- VA Office of Research and Development
Pulmonary Disease, Chronic Obstructive, COPD
26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Stage 1 of the study is designed to provide data about the risk-benefit of 4 dose regimens of indacaterol (75, 150, 300 \& 600 µg o.d.) in order to select two doses to carry forward into study Stage 2.
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
- Trial name
- NCT00463567
- Testing
- Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.)
- Where
- 344 sites in United States, Argentina and 10 more
- Volunteers
- 2,059 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease, Pulmonary Emphysema
Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine whether the cell therapy with bone marrow mononuclear cells is safe in the treatment of chronic obstructive pulmonary disease, specifically the pulmonary emphysema.
- Trial name
- COPD-01 (NCT01110252)
- Testing
- Stem cells stimulation, stem cells collection, stem cells infusion
- Where
- Brazil
- Volunteers
- 4 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Chronic Obstructive Pulmonary Disease
TOPIC Trial for COPD
The study is a randomized, double-blind, placebo-controlled, multiple-dose, pilot study of orally-administered ivacaftor in subjects with chronic obstructive pulmonary disease.
- Trial name
- NCT02135432
- Testing
- Ivacaftor
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Alabama at Birmingham
Pulmonary Disease, Chronic Obstructive
A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment
Study to collect the data on Chronic Obstructive Pulmonary Disease (COPD) patients who were administered with Long-Acting Beta-Agonist/ Long-Acting Muscarinic Antagonist (LABA/LAMA) (Fixed-dose Combination (FDC) or free combo) or…
- Trial name
- NCT04011475
- Testing
- Tiotropium + Olodaterol, Other LABA/LAMA, LAMA
- Where
- 12 sites in Taiwan
- Volunteers
- 1,617 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.